Navigation Links
Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
Date:5/19/2008

tements" that involve risks and uncertainties, including without limitation the risk that our results from early studies with PSI-7851 are not repeated in future studies, the risk that we are not able to gather the data and information necessary to, or that we otherwise cannot, file an IND for PSI-7851, the risk that PSI-7851 never becomes a product candidate or is never successfully developed and commercialized, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of any or all of our product candidates, the risk that we cannot enroll enough patients for the Phase 3 registration studies for clevudine, the risk that our collaboration with Roche will not continue or will not be successful, the risk that any one or more of our product candidates will not be successfully developed and commercialized and the risk that we will not be able to further develop any of the compounds from the new series of anti-HCV molecules currently being investigated by us. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
11. Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... AVIV, Israel , May 6, 2015  Galmed ... biopharmaceutical company focused on the development and commercialization of ... diseases and cholesterol gallstones, announced today that it will ... 13, 2015 to discuss results for the period ended ... current developments with respect to its clinical program for ...
(Date:5/6/2015)... , May 6, 2015 Neuralstem, Inc. (NYSE ... technology to develop small molecule and cell therapy treatments ... Jonathan Lloyd Jones to the position of ... Mr. Lloyd Jones brings to ... and business development experience.   Most recently, Mr. Lloyd ...
(Date:5/6/2015)... BOSTON, May 6, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: ... financial results for the three-month period ended March 31, ... were $8.3 million, an increase of 19% as compared ... , Product revenues increased 41% year-over-year, enabled by ... shipments to Merck Serono in the fourth quarter of ...
Breaking Medicine Technology:Galmed Pharmaceuticals First Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, May 13, 2015 2Galmed Pharmaceuticals First Quarter 2015 Conference Call and Webcast Scheduled for Wednesday, May 13, 2015 3Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer 2Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer 3Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer 4Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 2Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 3Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 4Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 5Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 6Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 7Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 8Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 9Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 10Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 11
(Date:5/6/2015)... San Mateo, Calif. (PRWEB) May 06, 2015 ... SafeMonk today announced a strategic partnership to ... in the cloud. The two industry-leading companies are teaming ... encryption platform. , “We’re thrilled to welcome ... meaningful to us that the people behind SafeMonk, the ...
(Date:5/6/2015)... Aging2.0 - the global network ... lineup of speakers and sponsors for its second annual ... for May 18-19 in San Francisco, brings together a ... investors and more than 50 startups from around the ... new products and services for the aging population. ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 In celebration of ... wigs giveaway. Every month they will give away a deluxe ... They listed a few steps to enter on a third-party ... at random, so anyone can be the winner. , The ... PremierLaceWigs.com has been the destination for such a jewel for ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 The American ... nomination period for its prestigious Integrated Water Resources Management ... IWRM approach to water resources projects. , An IWRM approach ... our establishment in 1964. In 2014, 12 projects were nominated ... IMPACT magazine features not only the 2014 AWRA IWRM Award ...
(Date:5/6/2015)... May 06, 2015 The Jefferson ... dedicated to activating and celebrating public service, announced ... Highmark Health, as an Outstanding Employee Volunteer Organization. ... Jefferson Awards Foundation, are dedicated to building a ... a decade, Highmark Health has recognized employees who ...
Breaking Medicine News(10 mins):Health News:Sookasa Grows Globally With SafeMonk Partnership 2Health News:Sookasa Grows Globally With SafeMonk Partnership 3Health News:Aging2.0 Global Innovation Summit Provides Unique Forum to Discover New Technologies and Develop Partnerships in the Senior Care Market 2Health News:Aging2.0 Global Innovation Summit Provides Unique Forum to Discover New Technologies and Develop Partnerships in the Senior Care Market 3Health News:Aging2.0 Global Innovation Summit Provides Unique Forum to Discover New Technologies and Develop Partnerships in the Senior Care Market 4Health News:PremierLaceWigs.com Human Hair Lace Wigs Giveaway Could Change Your Hairstyle 2Health News:Nominations Sought for Integrated Water Resources Management (IWRM) Award 2Health News:The Jefferson Awards Foundation Honors Highmark Health 2Health News:The Jefferson Awards Foundation Honors Highmark Health 3Health News:The Jefferson Awards Foundation Honors Highmark Health 4
... DCM is a condition which occurs when the heart becomes ... blood efficiently. The condition affects 35 in every 100,000 people. ... study published in the journal Science that a defect in ... key role in regulating the flow of calcium through the ...
... the Johns Hopkins School of Public Health has caused concerns ... urgent research into the impact of soya on unborn children ... can damage the male reproductive organs. Though there is no ... its effects on rats were so severe that// researchers believe ...
... in blood has been believed to be the ... of heart disease is associated with increased levels ... between LDL(Low-Density Lipoprotein)or 'bad' cholesterol and HDL(High-Density Lipoprotein) ... However, researchers in Canada and Sweden are now ...
... killers and both in developed and developing countries heart ... lost - through premature death and disability. Researchers at ... of measures that could reduce the number of years ... measures could be divided// into non-personal and personal. Non-personal ...
... ghrelin, has been identified by researchers from the Oregon ... of the hormone on the brain and have shown ... hypothalamus involved in weight regulation. Ghrelin is a hormone ... feeding when introduced to specialized weight regulating brain cells ...
... A recent study by researchers at the University of Durham ... benefit to the long list of already existing ones, for ... are at much less risk of being smothered than babies ... and their babies who were filmed at night while they ...
Cached Medicine News:Health News:Scientists locate key hormone involved in appetite control 2
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Inquire...
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
Medicine Products: